Involvement of μ1-opioid receptor on oxycodone-induced antinociception in diabetic mice

European Journal of Pharmacology

Volumn 560, Issue 2-3, 2007, Pages 160-162

  Nozaki, Chihiro ^a   Kamei, Junzo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Opioid receptor; 1 Opioid receptor; Diabetes; Hyperalgesia; Oxycodone

Indexed keywords

BETA FUNALTREXAMINE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALOXONAZINE; NORBINALTORPHIMINE; OXYCODONE; BETA-FUNALTREXAMINE; DRUG DERIVATIVE; NALOXONE; NALTREXONE; NARCOTIC ANALGESIC AGENT; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SELECTIVITY; HYPERALGESIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; TAIL FLICK TEST; ANIMAL; CLASSIFICATION; EXPERIMENTAL DIABETES MELLITUS; INSTITUTE FOR CANCER RESEARCH MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANALGESICS, OPIOID; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; MALE; MICE; MICE, INBRED ICR; NALOXONE; NALTREXONE; OXYCODONE; RECEPTORS, OPIOID, MU; STREPTOZOCIN;

EID: 33847370645     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.01.021     Document Type: Article

References (22)

1. Beaver W.T., Wallenstein S.L., Rogers A., and Houde R.W. Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. J. Pharmacol. Exp. Ther. 207 (1978) 92-100
2. Chen S.R., and Pan H.L. Antinociceptive effect of morphine, but not μ opioid receptor number, is attenuated in the spinal cord of diabetic rats. Anesthesiology 99 (2003) 1409-1414
3. Chen S.R., Sweigart K.L., Lakoski J.M., and Pan H.L. Functional μ opioid receptors are reduced in the spinal cord dorsal horn in rats. Anesthesiology 97 (2002) 1602-1608
4. D'Amour F.E., and Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72 (1941) 74-79
5. Endoh T., Matsuura H., Tanaka C., and Nagase H. Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch. Int. Pharmacodyn. Ther. 316 (1992) 30-42
6. Heyman J.S., Williams C.L., Burks T.F., Mosberg H.I., and Porreca F. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine. J. Pharmacol. Exp. Ther. 245 (1988) 238-243
7. Jolivalt C.G., Jiang Y., Freshwater J.D., Bartoszyk G.D., and Calcutt N.A. Dynorphin A, kappa opioid receptors and the antinociceptive efficacy of asimadoline in streptozotocin-induced diabetic rats. Diabetologia 49 (2006) 2775-2785
8. Kalso E., Vainio A., Mattila M.J., Rosenburg P.H., and Seppala T. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol. Toxicol. 67 (1990) 322-328
9. Kamei J., Ohhashi Y., Aoki T., Kawasima N., and Kasuya Y. Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by μ-opioid agonists, but not by δ- and κ-opioid agonists. Brain Res. 571 (1992) 199-203
10. Kamei J., Kawasima N., and Kasuya Y. Role of spleen or spleen products in the deficiency in morphine-induced analgesia in diabetic mice. Brain Res. 576 (1992) 139-142
11. 2-opioid receptors. Neurosci. Lett. 165 (1994) 141-143
12. Kamei J., Ohsawa M., Saitoh A., Iwamoto Y., Suzuki T., Misawa M., Nagase H., and Kasuya Y. Modification of μ-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes. J. Pharmacol. Exp. Ther. 274 (1995) 700-706
13. Kamei J., Zushida K., Ohsawa M., and Nagase H. The antinociceptive effects of endomorphin-1 and endomorphin-2 in diabetic mice. Eur. J. Pharmacol. 391 (2000) 91-96
14. Kamei J., Zushida K., Morita K., Sasaki M., and Tanaka S. Role of vanilloid VR1 receptor in thermal allodynia and hyperalgesia in diabetic mice. Eur. J. Pharmacol. 422 (2001) 83-86
15. Nozaki C., Saitoh A., Tamura N., and Kamei J. Antinociceptive effect of oxycodone in diabetic mice. Eur. J. Pharmacol. 524 (2005) 75-79
16. 5]enkephalin-induced antinociception in diabetic mice. Eur. J. Pharmacol. 339 (1997) 27-31
17. Ohsawa M., and Kamei J. Role of intracellular calcium in thermal allodynia and hyperalgesia in diabetic mice. Brain Res. 833 (1999) 278-281
18. Ohsawa M., Mizoguchi H., Narita M., Kamei J., Nagase H., and Tseng L.F. Effects of a μ-opioid receptor agonist on G-protein activation in streptozotocin-induced diabetic mice. Eur. J. Pharmacol. 401 (2000) 55-58
19. Ross F.B., and Smith M.T. The intrinsic antinociceptive effects of oxycodone appear to be κ-opioid receptor mediated. Pain 73 (1997) 151-157
20. Simon G.S., and Dewey W.L. Narcotics and diabetes. I. The effects of streptozotocin-induced diabetes on the antinociceptive potency of morphine. J. Pharmacol. Exp. Ther. 218 (1981) 318-323
21. Suzuki Y., Goto K., Shiizaki K., Omiya Y., Ishige A., Komatsu Y., and Kamei J. Antinociceptive effect of U-50488H, a κ-opioid agonist, in streptozotocin-induced diabetic mice. J. Pharm. Pharmacol. 53 (2001) 521-526
22. Watanabe H., Sakurada W., Mizoguchi H., Watanabe C., Fujimura H., Sakurada T., and Sakurada S. Involvement of the endogenous opioid peptide on the antinociception induced by endomorphin-2 in the mouse spinal site. J. Pharm. Sci. 100 Supplement I (2006) 71